Saturday, 31 October 2026European Markets

ACTEOS Stock Over 15% Down So Far On Tuesday

Loading stream...

acteos (cac 40: eos.pa), a french supply chain management software firm, experienced an unexpected drop of 15.82% tuesday. this came as quite an eye-opener as only 0.71% had declined on its index (to eur7,444.77) indicating bearish signs in the market.

analysis of acteos's market performance

acteos' last closing price of eur1.58 marked an 18.56% decline from its 52-week high of eur1.94. it is evident that acteos isn't immune to market volatility as its intraday variation varied between 0.44% and 2.02% in each of its last week, month and quarter periods; with average volatility peaking at 1.52% per week/month/quarter respectively reflecting its uncertain fate. additionally, the company reported an earnings per share (eps) value of eur-0.05 over its last twelve month financial period, reflecting losses in profitability.

market sentiments and acteos's performance

acteos's steep drop could be explained by both its financial performance and overall market sentiment, such as investor reservations about profitability. furthermore, global economic malaise could further erode stock values further.

about acteos

acteos was established in 1986 and offers an array of services such as its acteos suite, mobility solutions, software-as-a-service offerings, hotline assistance, technical project management, technical project consulting and project consulting throughout france, germany and lebanon.

more news about acteos (eos.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com